# Dexmedetomidine Addition to Morphine in Patients With Metastatic Cancer

> **NCT03936205** · PHASE2,PHASE3 · COMPLETED · sponsor: **Hotel Dieu de France Hospital** · enrollment: 18 (actual)

## Conditions studied

- Refractory Pain
- Metastatic Cancer

## Interventions

- **DRUG:** Dexmedetomidine

## Key facts

- **NCT ID:** NCT03936205
- **Lead sponsor:** Hotel Dieu de France Hospital
- **Sponsor class:** OTHER
- **Phase:** PHASE2,PHASE3
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2016-08
- **Primary completion:** 2017-10
- **Final completion:** 2017-10
- **Target enrollment:** 18 (ACTUAL)
- **Last updated:** 2019-05-14


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT03936205

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT03936205, "Dexmedetomidine Addition to Morphine in Patients With Metastatic Cancer". Retrieved via AI Analytics 2026-06-25 from https://api.ai-analytics.org/clinical/NCT03936205. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*